Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000856540> ?p ?o ?g. }
- W2000856540 endingPage "304" @default.
- W2000856540 startingPage "297" @default.
- W2000856540 abstract "ObjectiveHuman telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase. In B-cell chronic lymphocytic leukemia (B-CLL), telomerase activity is increased in about 75% of patients. The aim of this study was to analyze whether B-CLL patients with telomerase-positive leukemic cells had naturally occurring, telomerase-specific T cells that might be utilized for immune-mediated lysis of autologous tumor cells.MethodsSpontaneous T-cell immunity and cytotoxicity against hTERT was explored in B-CLL. Nineteen of 25 B-CLL patients (76%) expressed hTERT (reverse transcriptase polymerase chain reaction) and 10 were selected for specific T-cell analysis against hTERT.ResultsThe stimulation index (SI) of T cells from seven telomerase-positive patients stimulated with a 16aa hTERT peptide (611–626) loaded onto dendritic cells (DC) was 33.9 ± 15.4 (mean SI ± standard error of mean) and 13.2 ± 5.6 against a Ras control peptide (p = 0.05), whereas the corresponding SI values for three telomerase-negative patients were 5.3 ± 5.3 against the hTERT 611-626 peptide and 10.3 ± 6.5 against the Ras peptide, respectively; and for three healthy controls, 5.4 ± 0.9 against the hTERT 611-626 peptide and 4.5 ± 1.0 against the Ras peptide (both not significant). Blocking experiments revealed that the specific responses were major histocompatibility complex (MHC) class I and MHC class II restricted. DC pulsed with the hTERT-peptide generated MHC class I-restricted, hTERT-specific cytotoxic T lymphocytes in six of seven telomerase-positive patients; mean cytotoxicity of hTERT-stimulated T cells was 49.8% ± 9.3% vs 13.1 ± 2.9% for Ras-stimulated T cells (p < 0.05). In three of three telomerase-negative patients, no hTERT-specific cytotoxic T lymphocytes could be expanded.ConclusionTelomerase-positive B-CLL patients have spontaneously occurring cytotoxic hTERT-specific T cells. This antigen might be explored as a therapeutic vaccine in B-CLL. Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase. In B-cell chronic lymphocytic leukemia (B-CLL), telomerase activity is increased in about 75% of patients. The aim of this study was to analyze whether B-CLL patients with telomerase-positive leukemic cells had naturally occurring, telomerase-specific T cells that might be utilized for immune-mediated lysis of autologous tumor cells. Spontaneous T-cell immunity and cytotoxicity against hTERT was explored in B-CLL. Nineteen of 25 B-CLL patients (76%) expressed hTERT (reverse transcriptase polymerase chain reaction) and 10 were selected for specific T-cell analysis against hTERT. The stimulation index (SI) of T cells from seven telomerase-positive patients stimulated with a 16aa hTERT peptide (611–626) loaded onto dendritic cells (DC) was 33.9 ± 15.4 (mean SI ± standard error of mean) and 13.2 ± 5.6 against a Ras control peptide (p = 0.05), whereas the corresponding SI values for three telomerase-negative patients were 5.3 ± 5.3 against the hTERT 611-626 peptide and 10.3 ± 6.5 against the Ras peptide, respectively; and for three healthy controls, 5.4 ± 0.9 against the hTERT 611-626 peptide and 4.5 ± 1.0 against the Ras peptide (both not significant). Blocking experiments revealed that the specific responses were major histocompatibility complex (MHC) class I and MHC class II restricted. DC pulsed with the hTERT-peptide generated MHC class I-restricted, hTERT-specific cytotoxic T lymphocytes in six of seven telomerase-positive patients; mean cytotoxicity of hTERT-stimulated T cells was 49.8% ± 9.3% vs 13.1 ± 2.9% for Ras-stimulated T cells (p < 0.05). In three of three telomerase-negative patients, no hTERT-specific cytotoxic T lymphocytes could be expanded. Telomerase-positive B-CLL patients have spontaneously occurring cytotoxic hTERT-specific T cells. This antigen might be explored as a therapeutic vaccine in B-CLL." @default.
- W2000856540 created "2016-06-24" @default.
- W2000856540 creator A5049924304 @default.
- W2000856540 creator A5050210583 @default.
- W2000856540 creator A5052339023 @default.
- W2000856540 creator A5066945399 @default.
- W2000856540 creator A5069881022 @default.
- W2000856540 creator A5070030873 @default.
- W2000856540 date "2007-02-01" @default.
- W2000856540 modified "2023-10-18" @default.
- W2000856540 title "Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells" @default.
- W2000856540 cites W1253046850 @default.
- W2000856540 cites W1540861788 @default.
- W2000856540 cites W1543500873 @default.
- W2000856540 cites W1968927360 @default.
- W2000856540 cites W2000971601 @default.
- W2000856540 cites W2003862674 @default.
- W2000856540 cites W2008808050 @default.
- W2000856540 cites W2010979801 @default.
- W2000856540 cites W2014709975 @default.
- W2000856540 cites W2017591700 @default.
- W2000856540 cites W2030976397 @default.
- W2000856540 cites W2031651417 @default.
- W2000856540 cites W2036594498 @default.
- W2000856540 cites W2049757773 @default.
- W2000856540 cites W2052986175 @default.
- W2000856540 cites W2057543822 @default.
- W2000856540 cites W2063418078 @default.
- W2000856540 cites W2063914679 @default.
- W2000856540 cites W2064507032 @default.
- W2000856540 cites W2072696666 @default.
- W2000856540 cites W2076976919 @default.
- W2000856540 cites W2079378073 @default.
- W2000856540 cites W2097521725 @default.
- W2000856540 cites W2110727184 @default.
- W2000856540 cites W2115346781 @default.
- W2000856540 cites W2124454332 @default.
- W2000856540 cites W2124603192 @default.
- W2000856540 cites W2126815966 @default.
- W2000856540 cites W2128587093 @default.
- W2000856540 cites W2143859021 @default.
- W2000856540 cites W2149421090 @default.
- W2000856540 cites W2155043438 @default.
- W2000856540 cites W2158164503 @default.
- W2000856540 cites W4249802798 @default.
- W2000856540 cites W60865865 @default.
- W2000856540 doi "https://doi.org/10.1016/j.exphem.2006.10.006" @default.
- W2000856540 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17258078" @default.
- W2000856540 hasPublicationYear "2007" @default.
- W2000856540 type Work @default.
- W2000856540 sameAs 2000856540 @default.
- W2000856540 citedByCount "55" @default.
- W2000856540 countsByYear W20008565402012 @default.
- W2000856540 countsByYear W20008565402013 @default.
- W2000856540 countsByYear W20008565402014 @default.
- W2000856540 countsByYear W20008565402016 @default.
- W2000856540 countsByYear W20008565402017 @default.
- W2000856540 countsByYear W20008565402018 @default.
- W2000856540 countsByYear W20008565402019 @default.
- W2000856540 countsByYear W20008565402020 @default.
- W2000856540 countsByYear W20008565402021 @default.
- W2000856540 countsByYear W20008565402022 @default.
- W2000856540 countsByYear W20008565402023 @default.
- W2000856540 crossrefType "journal-article" @default.
- W2000856540 hasAuthorship W2000856540A5049924304 @default.
- W2000856540 hasAuthorship W2000856540A5050210583 @default.
- W2000856540 hasAuthorship W2000856540A5052339023 @default.
- W2000856540 hasAuthorship W2000856540A5066945399 @default.
- W2000856540 hasAuthorship W2000856540A5069881022 @default.
- W2000856540 hasAuthorship W2000856540A5070030873 @default.
- W2000856540 hasBestOaLocation W20008565401 @default.
- W2000856540 hasConcept C104317684 @default.
- W2000856540 hasConcept C109316439 @default.
- W2000856540 hasConcept C125593758 @default.
- W2000856540 hasConcept C147483822 @default.
- W2000856540 hasConcept C153911025 @default.
- W2000856540 hasConcept C154317977 @default.
- W2000856540 hasConcept C177336024 @default.
- W2000856540 hasConcept C185592680 @default.
- W2000856540 hasConcept C202751555 @default.
- W2000856540 hasConcept C203014093 @default.
- W2000856540 hasConcept C2776090121 @default.
- W2000856540 hasConcept C2777938653 @default.
- W2000856540 hasConcept C2778461978 @default.
- W2000856540 hasConcept C502942594 @default.
- W2000856540 hasConcept C552990157 @default.
- W2000856540 hasConcept C55493867 @default.
- W2000856540 hasConcept C86803240 @default.
- W2000856540 hasConcept C8891405 @default.
- W2000856540 hasConcept C94581717 @default.
- W2000856540 hasConceptScore W2000856540C104317684 @default.
- W2000856540 hasConceptScore W2000856540C109316439 @default.
- W2000856540 hasConceptScore W2000856540C125593758 @default.
- W2000856540 hasConceptScore W2000856540C147483822 @default.
- W2000856540 hasConceptScore W2000856540C153911025 @default.
- W2000856540 hasConceptScore W2000856540C154317977 @default.
- W2000856540 hasConceptScore W2000856540C177336024 @default.
- W2000856540 hasConceptScore W2000856540C185592680 @default.